[{"orgOrder":0,"company":"Grand River Aseptic Manufacturing","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Ad26.COV2-S","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Grand River Aseptic Manufacturing","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Grand River Aseptic Manufacturing \/ Johnson & Johnson","highestDevelopmentStatusID":"10","companyTruncated":"Grand River Aseptic Manufacturing \/ Johnson & Johnson"},{"orgOrder":0,"company":"Grand River Aseptic Manufacturing","sponsor":"Bavarian Nordic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Live Nonreplicating Smallpox And Monkeypox Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Grand River Aseptic Manufacturing","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Grand River Aseptic Manufacturing \/ Bavarian Nordic","highestDevelopmentStatusID":"12","companyTruncated":"Grand River Aseptic Manufacturing \/ Bavarian Nordic"}]

Find Clinical Drug Pipeline Developments & Deals by Grand River Aseptic Manufacturing

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : JYNNEOS is a suspension for subcutaneous injection (0.5 mL) based on a live, attenuated vaccinia virus (Modified Vaccinia Ankara, MVA-BN), incapable of replicating in the body, yet still capable of eliciting a potent immune response.

                          Brand Name : Jynneos

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          August 19, 2022

                          Lead Product(s) : Live Nonreplicating Smallpox And Monkeypox Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Bavarian Nordic

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : The agreement includes the technical transfer and fill and finish manufacture of Johnson & Johnson's SARS-CoV-2 vaccine candidate.

                          Brand Name : JNJ-78436735

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          September 25, 2020

                          Lead Product(s) : Ad26.COV2-S

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Johnson & Johnson

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank